Vor Biopharma Inc.
VOR
$0.59
-$0.044-6.94%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -12.12% | -9.39% | -4.80% | 4.57% | 9.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.85% | -3.78% | 12.01% | 26.62% | 34.92% |
| Operating Income | 3.85% | 3.78% | -12.01% | -26.62% | -34.92% |
| Income Before Tax | 0.81% | 2.64% | -11.29% | -22.95% | -27.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.81% | 2.64% | -11.29% | -22.95% | -27.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.81% | 2.64% | -11.29% | -22.95% | -27.98% |
| EBIT | 3.85% | 3.78% | -12.01% | -26.62% | -34.92% |
| EBITDA | 3.99% | 4.16% | -12.03% | -26.75% | -34.82% |
| EPS Basic | 3.01% | 12.88% | 14.32% | 17.69% | 25.06% |
| Normalized Basic EPS | 3.00% | 12.87% | 14.32% | 17.70% | 25.06% |
| EPS Diluted | 3.01% | 12.88% | 14.32% | 17.69% | 25.06% |
| Normalized Diluted EPS | 3.00% | 12.87% | 14.32% | 17.70% | 25.06% |
| Average Basic Shares Outstanding | 2.26% | 10.69% | 25.42% | 44.58% | 69.95% |
| Average Diluted Shares Outstanding | 2.26% | 10.69% | 25.42% | 44.58% | 69.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
